Brighthouse Financial heads into its Q1 2026 earnings today with a short position that has quietly built without any accompanying squeeze pressure — a combination that makes the lending market worth watching alongside the actual results.
Short interest is running at 11.6% of the free float, up around 2% over the past month, making it one of the more heavily shorted names in the insurance sector. Yet the borrow market tells a relaxed story. Cost to borrow is just 0.51% — cheap by any standard, even after rising about 7% on the week and 26% over the past month. Borrow availability has eased significantly from its April peak: availability was at its tightest around April 17, when utilization hit its 52-week high, but has since loosened materially. The net picture is that bears have meaningful conviction — 11.6% short interest is real — but they are not paying up to hold those positions. There is no squeeze dynamic building in the lending pool right now. Options traders are similarly composed. The put/call ratio is essentially flat at 1.02, right in line with its 20-day average, and a world away from last month's more defensive readings above 1.05. Investors have spent the past several weeks quietly reducing downside protection.
The analyst community has cooled on Brighthouse over a longer arc. The consensus is a collective hold, with seven analysts clustered there and a mean price target around $65 — just 4% above Tuesday's close of $62.57. Recent coverage actions are notable for their caution: Barclays moved to Equal-Weight in January while holding its target flat, and Raymond James dropped from Strong Buy to Market Perform back in November 2025. The most recent action, Keefe, Bruyette & Woods reinstating at Market Perform with a $67 target in late March, confirms the dominant view — the Street sees limited upside at current levels and no compelling reason to press either direction. The forward earnings picture is more interesting: the 12-month forward EPS estimate ranks in the top 3% of the universe for year-on-year improvement, yet the trailing EPS surprise rank sits at just the 17th percentile — meaning revisions have been optimistic before, but delivery has been inconsistent. The stock trades at a P/E of around 3.2x and a P/B of 0.58x, metrics that look depressed even for a life and health insurer navigating a complex macro backdrop. The price is up about 5% over the past month, recovering from a deeper hole — down roughly 3% year-to-date — and the RSI at 67 puts it in mild overbought territory ahead of the print.
The institutional register adds one notable detail. HBK Investments and Glazer Capital each appear as new entrants in the holder list as of December 2025, both building positions in the hundreds of millions of shares. Greenlight Capital also holds a material 4.9% stake with no change reported since year-end. That kind of concentrated, event-oriented ownership — alongside a Soros Fund Management position — suggests a subset of the holder base is specifically positioned around a corporate event or valuation catalyst, not just passive allocation. Insider activity has been largely awards and modest tax-related selling rather than discretionary buying or selling, with the CEO and CFO receiving equity grants in early March alongside small sell-to-cover transactions.
The Q1 print is effectively a test of whether the forward earnings optimism — the top-3% EPS revision trajectory — is grounded in something the company can actually demonstrate at the bottom line, or whether the pattern of disappointing relative to elevated estimates reasserts itself.
See the live data behind this article on ORTEX.
Open BHF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
